United States Patent 7,030,149 Scope and Claims: Brimonidine 0.2% + Timolol 0.5% Fixed-Dose Ocular Hypertension Regimen (Claim-by-Claim, Estate Map, and Generic-Risk Outlook)
Executive summary: U.S. Patent 7,030,149 claims a fixed-combination topical glaucoma/ocular hypertension regimen using brimonidine 0.2% by weight and timolol 0.5% by weight in a single composition, dosed twice daily, positioned as equivalent to the prior standard of separate brimonidine (0.2%) three times daily plus timolol (0.5%) twice daily. Dependent claims narrow the composition by adding benzalkonium chloride (BAK) 0.001% to 0.01% (preferred ~0.005%). The patent’s enforceable scope is therefore centered on (i) the dose concentrations, (ii) the fixed-combination packaging into a single topical composition, (iii) the twice-daily schedule, (iv) equivalence to a specific separate-dosing reference regimen, and (v) an optional preservative concentration band if BAK is present.
What does US Patent 7,030,149 claim for glaucoma treatment, and what is the protected dosing regimen?
Claim 1: the core fixed-combination method with twice-daily equivalence
Claim 1 defines a method of treating glaucoma or ocular hypertension using:
- Topical administration to an eye
- Single composition containing:
- About 0.2% brimonidine by weight
- About 0.5% timolol by weight
- As the sole active agents
- Dosing frequency: twice a day
- Comparative efficacy limitation: the method is as effective as:
- 0.5% timolol twice a day, plus
- 0.2% brimonidine three times a day
- Separate compositions comparator explicitly requires that, in the comparator regimen, the two compounds are in separate compositions.
Scope implications (what a challenger must “design around”):
- Fixed combination requirement: infringement is tied to both actives being in one composition administered to the same eye in the claimed regimen.
- Concentration guardrails: “about 0.2%” brimonidine and “about 0.5%” timolol. This typically invites claim construction for tolerances, but the claim is still anchored to those endpoints.
- Schedule constraint: “twice a day” is not incidental; it is an express limitation.
- Equivalence clause as a method limitation: the claim reads like a method requiring therapeutic performance. In practice, this is often litigated via evidence of clinical equivalence to the specified separate regimen.
- “Sole active agents”: other drug actives (even at low levels) in the single composition can take the accused product outside literal scope, depending on how “sole active agents” is construed.
Claim 1’s functional “as effective as” bottleneck
The claim does not just recite dosing. It also requires effectiveness relative to a comparator schedule and formulation structure (separate compositions). That comparative language tends to:
- Anchor trial evidence to specific reference regimens.
- Provide an argument against products that are on-paper similar but fail to meet the comparative performance.
What additional composition limits are protected in US 7,030,149 claims 2 and 3 (benzalkonium chloride range)?
Claim 2: BAK inclusion band
Claim 2 adds that the single composition “further comprises”:
- from 0.001% to 0.01% benzalkonium chloride
Claim 3: preferred BAK concentration
Claim 3 narrows to:
- about 0.005% benzalkonium chloride
Scope implications:
- Claims 2–3 are dependent. They only apply if the base limitations of claim 1 are met (fixed-combination, 0.2% brimonidine, 0.5% timolol, sole actives, twice daily, efficacy comparator).
- For a product that contains no BAK or contains BAK outside this range, literal infringement of claims 2–3 is reduced. However, claim 1 may still be asserted because claim 1 does not require BAK.
How does claim 4 reframe the method as “reducing doses” without efficacy loss?
Claim 4: dose-reduction framing tied to twice-daily fixed combination
Claim 4 recites the same essentials but as a specific clinical objective:
- Reduce daily doses of brimonidine from 3 times a day to 2 times a day
- Without loss of efficacy
- With:
- brimonidine 0.2% by weight
- brimonidine + timolol (single composition) at:
- Dosing structure: administering the single composition containing both actives to achieve the brimonidine schedule reduction.
Scope implications:
- Claim 4 is aimed at products that achieve the schedule consolidation for brimonidine dosing while maintaining efficacy.
- It reinforces the equivalence concept, but focuses the method on the brimonidine dosing burden reduction.
What is the likely patent scope boundary: fixed combination vs separate dosing and dose schedule?
Hard infringement characteristics
Based strictly on the claim language, the following are high-risk features for a competitor:
- Single composition containing both actives (brimonidine + timolol).
- Brimonidine concentration near 0.2% and timolol concentration near 0.5%.
- Twice-daily regimen.
- Sole actives condition (no other pharmacologically active components in the same composition).
Primary design-arounds consistent with the claim structure
Low-risk paths for a filer typically include at least one of:
- Use of a separate-composition regimen (even if the patient receives effectively equivalent daily exposure), because claim 1 explicitly contrasts to separate compositions.
- Using a different dosing frequency for brimonidine that does not match the claimed twice daily.
- Adding an additional active agent in the same composition (to defeat the “sole active agents” language), depending on how “active” is determined.
- Moving BAK outside the 0.001%–0.01% range to avoid claims 2–3 (but not necessarily claim 1).
How strong is the patent estate for brimonidine 0.2% + timolol 0.5% fixed combination beyond US 7,030,149?
No additional patent numbers, continuation claims, or related US publications were provided in the prompt. A complete estate map requires those documents and assignment/patent-family identifiers; absent that data, an estate-level strength score cannot be produced.
What patents likely overlap in US Orange Book entry strategy for brimonidine/timolol products?
No Orange Book-listed reference products or application numbers were provided. Without the specific FDA reference product and associated listed patents, a correct overlap analysis of “what else claims the same fixed-dose” cannot be generated.
Does US 7,030,149 cover fixed combination marketed products, generics, or reformulations?
Coverage is not limited by dosage form in the claim text you provided
Claim 1 and its dependents are framed as topical administration of a composition. If the accused product is a topical ophthalmic solution/gel/other form that delivers the specified concentrations and schedule, dosage form could be argued as not limiting unless the patent file history or specification introduces additional constraints.
Key risk: “sole active agents”
If a competitor’s composition includes other pharmacologically active components, literal infringement risk drops under claim construction of “sole active agents.” Reformulations with preservatives only likely remain within the “active agents” limitation, but they can still alter literal applicability to claims 2–3 if BAK is changed.
What generic entry risks exist under Paragraph IV theory for methods claimed in US 7,030,149?
For a Paragraph IV ANDA-type filing (small molecules), a common legal structure is:
- Challenge the listed patent as invalid and/or not infringed.
- Argue noninfringement by differences in formulation (actives, preservatives, concentrations), dosing schedule, or performance relative to the comparator.
Given the claim language provided, the most targeted noninfringement theories are:
- Not a single composition (separate actives).
- Different schedule (not twice-daily).
- Different concentrations (not about 0.2% brimonidine and about 0.5% timolol).
- Not “sole active agents” (extra active added).
- BAK out of range (for dependent claims 2–3).
A validity attack typically focuses on whether the “as effective as” equivalence is supported and whether fixed combination/twice-daily dose schedules were obvious over prior art. However, without the underlying specification and prosecution record, a litigation-ready strength assessment cannot be made from claim text alone.
When does US 7,030,149 lose exclusivity (expiration and PTA)?
No filing date, priority date, patent term adjustment (PTA), terminal disclaimer, or maintenance status data was provided. Without those, exclusivity timing cannot be stated accurately.
Key Takeaways
- US 7,030,149 centers on a fixed-combination method: brimonidine 0.2% + timolol 0.5% in one topical composition, dosed twice daily for glaucoma or ocular hypertension.
- The method is tethered to an efficacy-equivalence comparator: as effective as separate dosing of timolol 0.5% twice daily plus brimonidine 0.2% three times daily.
- Claims 2–3 add a BAK constraint: 0.001% to 0.01% (preferred ~0.005%) benzalkonium chloride.
- Claim 4 strengthens the clinical framing as reducing brimonidine dosing frequency from three to two daily administrations without efficacy loss.
- Design-around is claim-structure driven: fixed vs separate dosing, dosing frequency, concentrations, and the “sole active agents” requirement are the primary levers.
FAQs
1) What products would most clearly infringe US 7,030,149?
A topical ophthalmic product that delivers brimonidine ~0.2% and timolol ~0.5% as the only active agents in a single composition administered twice daily, for glaucoma/ocular hypertension, with effectiveness comparable to the specified separate regimen.
2) Does changing benzalkonium chloride concentration avoid infringement?
It can avoid claims 2–3 if BAK is outside 0.001%–0.01% (or not ~0.005%). It does not, by itself, avoid claim 1, which does not require BAK.
3) If a generic uses the same drug concentrations but doses brimonidine three times daily, is it covered?
Claim 1 and claim 4 are limited to a twice-daily schedule for the fixed-combination regimen. A three-times-daily regimen for brimonidine would not match the claimed method limitations as provided.
4) How does “single composition” matter in enforcement?
It is a core limitation. Regimens using separate compositions for brimonidine and timolol align with the comparator described in the claim and are the main structural noninfringement path.
5) If a competitor adds another active ingredient, can it avoid the patent?
Because claim 1 requires the composition has “sole active agents” of brimonidine and timolol, adding a third pharmacologically active ingredient can be a direct literal noninfringement strategy, subject to claim construction of “active agent.”
References
No sources were cited because only the claim text was provided and no bibliographic, FDA, prosecution, or Orange Book data accompanied the request.
